The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...

BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met ...

- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU) - RINVOQ is approved ...

Credit: Getty Images. The COAST-X trial was conducted in 305 biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients with nr-axSpA. Eli Lilly has announced top-line results from a phase ...

OAKVILLE, ON, Jan. 15, 2020 /CNW/ - UCB Canada Inc. announced today that Health Canada has approved CIMZIA ® (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial ...

The CHMP positive opinion was based on the findings from the GO-AHEAD study, which demonstrated significant clinical improvement in patients with active nr-axial SpA treated with golimumab, compared ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial ...

Please provide your email address to receive an email when new articles are posted on . Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from ...

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...

Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...